Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher N Hahn

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
Blood|March 8, 2024
IDH-mutant myeloid neoplasms are associated with seronegative rheumatoid arthritis and innate immune activationLih En Hong, Mihir D Wechalekar, Monika Kutyna, et al.
Leukemia|April 14, 2021
Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancerDeepak Singhal, Christopher N Hahn, Simone Feurstein, et al.
Leukemia|May 16, 2019
The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distributionDeepak Singhal, Li Yan A Wee, Monika M Kutyna, et al.
Blood|December 30, 2015
Novel germ line DDX41 mutations define families with a lower age of MDS/AML onset and lymphoid malignanciesMaya Lewinsohn, Anna L Brown, Luke M Weinel, et al.
Blood|August 17, 2022
Discovery of novel predisposing coding and noncoding variants in familial Hodgkin lymphomaJamie E Flerlage, Jason R Myers, Jamie L Maciaszek, et al.
Nature Genetics|September 6, 2011
Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemiaChristopher N Hahn, Chan-Eng Chong, Catherine L Carmichael, et al.
Science Translational Medicine|March 2, 2022
Pathogenic variants in <i>MDFIC</i> cause recessive central conducting lymphatic anomaly with lymphedemaAlicia B Byrne, Pascal Brouillard, Drew L Sutton, et al.
Blood Advances|March 14, 2025
Evidence-based risk stratification of myeloid neoplasms harboring TP53 mutationsMithun Vinod Shah, Kevin Hung, Anmol Baranwal, et al.
Blood Cancer Journal|May 7, 2025
Validation of the 5th edition of the World Health Organization and International Consensus Classification guidelines for TP53-mutated myeloid neoplasm in an independent international cohortMithun Vinod Shah, Kevin Hung, Anmol Baranwal, et al.
Nature Genetics|March 31, 2019
Genomic subtyping and therapeutic targeting of acute erythroleukemiaIlaria Iacobucci, Ji Wen, Manja Meggendorfer, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
Blood|March 8, 2024
IDH-mutant myeloid neoplasms are associated with seronegative rheumatoid arthritis and innate immune activationLih En Hong, Mihir D Wechalekar, Monika Kutyna, et al.
Leukemia|April 14, 2021
Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancerDeepak Singhal, Christopher N Hahn, Simone Feurstein, et al.
Leukemia|May 16, 2019
The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distributionDeepak Singhal, Li Yan A Wee, Monika M Kutyna, et al.
Blood|December 30, 2015
Novel germ line DDX41 mutations define families with a lower age of MDS/AML onset and lymphoid malignanciesMaya Lewinsohn, Anna L Brown, Luke M Weinel, et al.
Blood|August 17, 2022
Discovery of novel predisposing coding and noncoding variants in familial Hodgkin lymphomaJamie E Flerlage, Jason R Myers, Jamie L Maciaszek, et al.
Nature Genetics|September 6, 2011
Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemiaChristopher N Hahn, Chan-Eng Chong, Catherine L Carmichael, et al.
Science Translational Medicine|March 2, 2022
Pathogenic variants in <i>MDFIC</i> cause recessive central conducting lymphatic anomaly with lymphedemaAlicia B Byrne, Pascal Brouillard, Drew L Sutton, et al.
Blood Advances|March 14, 2025
Evidence-based risk stratification of myeloid neoplasms harboring TP53 mutationsMithun Vinod Shah, Kevin Hung, Anmol Baranwal, et al.
Blood Cancer Journal|May 7, 2025
Validation of the 5th edition of the World Health Organization and International Consensus Classification guidelines for TP53-mutated myeloid neoplasm in an independent international cohortMithun Vinod Shah, Kevin Hung, Anmol Baranwal, et al.
Nature Genetics|March 31, 2019
Genomic subtyping and therapeutic targeting of acute erythroleukemiaIlaria Iacobucci, Ji Wen, Manja Meggendorfer, et al.
Pageof 6